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The influenza A virus matrix protein 2 ectodomain (M2e) is a universal influenza A vaccine candidate. Numerous studies 
in laboratory mice, but very few in natural influenza A virus hosts, have demonstrated that M2e-based vaccines can provide 
protection against any influenza A virus challenge. M2e-based immunity is largely accomplished by IgG and early stage 
clinical studies have demonstrated that the vaccine is safe. Yet M2e is considered a difficult target to develop as a vaccine: it 
does not offer sterilizing immunity and its mode of action relies on Fcγ receptor-mediated effector mechanisms, most likely 
in concert with alveolar macrophages. In a human challenge study with an H3N2 virus, treatment with a monoclonal M2e-
specific human IgG was associated with a faster recovery compared to placebo treatment. If the universal influenza vaccine 
field incorporates this antigen into next generation vaccines, M2e could prove its merit when the next influenza pandemic 
strikes.
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The influenza A virus matrix protein 2 (M2) is essential for virus 
propagation. M2 was discovered by Robert Lamb, and it is now 
known that the protein fulfills at least 3 critical functions [1, 2]. 
First, its ion channel activity is required for the disassembly of 
the viral core. This process starts in the acidic environment of 
the endosomes, shortly after virion uptake by the infected cells. 
Initially, at a pH of 6.5–6.0, the M2 channel enables the flux of 
protons into the virion interior, which weakens the interactions 
between matrix protein 1 (M1) and the viral ribonucleoproteins 
(vRNPs) within the viral core. In the more acidic (pH 5.4–6.0) 
late endosomes, M2 also starts to conduct potassium ions into 
the virion, which results in the disruption of the vRNP-vRNP 
interactions [2, 3]. The ensuing pH-triggered hemagglutinin 
(HA)–mediated membrane fusion finally releases the “primed” 
vRNPs into the cytosol, ready to migrate to the nucleus where 
the viral transcription and replication can start. 
Second, M2 is required for virus assembly and budding. The 
membrane distal end of the cytoplasmic part of M2 interacts 
with M1, which leads to virion assembly [4]. The membrane 
proximal, cytoplasmic, amphipathic α-helix of M2 controls the 
budding process. In the plasma membrane of the infected cell, 
M2 accumulates at the rim of HA- and neuraminidase-con-
taining lipid rafts, alters membrane curvature. and eventually 
pinches off newly assembled virions [5]. Finally, M2 perturbs 
several host cell functions. In myeloid cells, its ion channel 
function may activate inflammasomes, whereas a conserved 
LC3-interacting motif close to the carboxyterminal end of its 
cytoplasmic domain interferes with autophagy (Figure 1A) [6, 
7]. The functional orthologue of M2 in influenza B virus is 
named BM2. Like M2, BM2 can shuttle protons across mem-
branes and it interacts with M1 of influenza B virus [8]. The 
sequences of M2 and BM2 are very different.
THE M2 ECTODOMAIN: CONSERVED, POORLY-
STRUCTURED, AND YET IMMUNOPROTECTIVE
The aminoterminal part of M2 that protrudes from the mem-
brane is the M2 ectodomain (M2e) and is 23 amino acid resi-
dues long. Its strong sequence conservation across all influenza 
A virus subtypes may suggest that M2e fulfills an important role 
in the virus life cycle, yet we know surprisingly little about its 
function. Presumably, M2e merely plays a role in controlling the 
N-out and C-in orientation of M2, a type III membrane protein, 
although there is no particular primary sequence requirement 
known for such a role, apart from a preference for an acidic resi-
due that precedes the transmembrane region [9, 10]. The part of 
genome segment 7 that codes for the first 9 amino acid residues 
of M2 is packed with information, which explains its very high 
sequence conservation. It comprises a packaging signal for viral 
RNA segment 7, the beginning of the open reading frame of 2 
different proteins (M1 and M2), as well as the splice donor for 
the M2 transcript [11]. The relative sequence conservation of 
amino acid residues 10–24 of M2e is dictated by the overlapping 
C-terminus of M1. This overlap is in a different reading frame 
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from that of M1 and also comprises the splice acceptor for the 
M2 messenger RNA (Figure 1B).
The first 9 amino acid residues of M1 (identical in M2) fold 
into an α-helix, which is part of a helical bundle structure that 
is conserved in orthomyxoviruses [12, 13]. Solid-state magnetic 
resonance analysis of M2 embedded in artificial lipid bilayers 
suggests that M2e can adopt a β-strand or, in the presence of 
cholesterol, an α-helical conformation [14]. An M2e peptide 
complexed with an antibody-derived fragment antigen-bind-
ing  (Fab) fragment, on the other hand, can fold in at least 2 
very different conformations dependent on the specificity of 
the monoclonal antibodies used [15, 16]. The interactions of the 
M2e residues with the antibody paratope revealed by these M2e 
peptide–Fab complexes explain why some influenza A viruses, 
which have a slightly different M2e sequence, could resist rec-
ognition by a particular monoclonal antibody. This suggests 
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Figure 1. Schematic representation of matrix protein 2 (M2). A, M2 is depicted as a tetrameric transmembrane protein composed of 2 dimers that are covalently linked by 
a disulfide bond between pairs of cysteines (red line). The M2 ectodomain (M2e), at the N-terminus, faces the extracellular side of the lipid bilayer that is represented by 2 
transparent gray parallelograms. The sequence conservation of M2e is illustrated by the listed sequences from diverse influenza A viruses (all from cases in humans). The 
red rectangles represent the transmembrane domain. The histidine and tryptophane residues at positions 37 and 41 of M2, respectively, are essential for the proton-selective 
ion channel activity and are shown in the single letter code. The blue ovals represent the α-helix required for virion budding. These helices are oriented nearly parallel with 
the cytoplasmic membrane. Near the C-terminus of the cytoplasmic domain of M2, a conserved FVXI motif is shown that is important for LC3 binding. The C-terminal part of 
M2 also interacts with matrix protein 1 (M1). B, Schematic diagram of the M1 and M2 open reading frames, illustrating the overlap between M2e and M1. The nucleotide 
and amino acid sequences represent the start and end of M1 and the start of M2 and are derived from A/Hong Kong/01/1968(H3N2). Abbreviations: SA, splice acceptor; 
SD, splice donor. 
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that the M2e peptide–Fab complexes are biologically relevant. It 
would be interesting to use modern, Å-resolution quality cryo-
electron microscopy to reveal how M2e-specific monoclonal 
antibodies bind their target in the context of a lipid membrane 
and to clarify, for example, whether any interaction of the anti-
body variable domains with the lipid membrane is implicated. 
Are the M2e moieties within a single M2 tetramer accessible 
for >1 Fab? Or would M2e-specific single-domain antibodies 
be needed to accomplish this? No M2e-specific antibodies that 
recognize quaternary surfaces on tetrameric proteins have yet 
been isolated.
Since the first report that a mouse immunoglobulin (Ig) G1 
monoclonal antibody directed against M2e, and the finding that 
active vaccination of mice with a full-length recombinant M2 
preparation or, more elegantly, with recombinant M2e-displaying 
virus-like particles, could protect mice against a potentially lethal 
influenza A virus challenge, hundreds of publications have con-
firmed the immunoprotective potency of M2e-based vaccines 
[17–19] (reviewed in 20). The main conclusions of these stud-
ies are that IgG antibodies specific for M2e are essential for the 
protection and that M2e-based immunity can reduce virus rep-
lication and disease associated with influenza A virus infection, 
and, importantly, can protect against challenge with any influenza 
A virus subtype. The extracellular part of BM2 is only 7 amino 
acid residues long, most likely too short to induce a meaningful 
antibody response. 
Some M2e-fusion constructs provide better protection than 
others. In general, recombinant nonenveloped viruslike parti-
cles (VLPs) as a carrier for M2e antigens are the preferred vac-
cine formats to elicit M2e-specific immune responses. Examples 
include the use of hepatitis B core and bacteriophage Qβ capsids, 
which have the advantage that they can be produced in pro-
karyotic expression systems using culture media that are free of 
animal-derived products [19, 21]. In addition, these VLPs can 
package immunostimulatory nucleic acids that induce T-helper 
1–biased adjuvant effects [21, 22]. Vaccination with M2e VLPs 
also results in a (strong) immune response directed against the 
carrier capsids, which has been considered acceptable by regu-
latory authorities for early-stage clinical testing of M2e vaccine 
candidates. However, the rollout of hepatitis B core-based VLPs 
to induce an immune response against a grafted antigen such 
as M2e could, in the longer run, confound the interpretation of 
serological diagnostic tests performed to assess a patient’s hepa-
titis B carrier status.
VLPs with multiple head-to-tail copies of M2e induce much 
stronger M2e-specific immune responses compared with single 
M2e fusion constructs, presumably because the antigen is better 
accessible for the B-cell receptor, and an avidity effect is created. 
This way, different M2e variants can also be incorporated into 
the same vaccine construct, which results in better coverage 
of the limited M2e diversity (M2e of human H3N2 and H1N1 
viruses that have circulated since 2009, for example, differs at 4 
positions). Such M2e repeats have been successfully fused with 
a tetramerizing leucine zipper followed by a transmembrane 
domain and produced as enveloped, insect cell–derived VLPs 
[23]. The use of decameric human respiratory syncytial virus 
nucleoprotein-based nanorings as carriers of tandem repeat 
copies of M2e has also been explored. These nanorings can be 
produced in Escherichia coli and induce robust protective anti–
M2e IgG and IgA responses after intranasal immunization of 
mice [24].
In general, genetic or vectored full-length M2 vaccine con-
structs induce a weak M2e-specific antibody response, which 
is in line with the naturally low humoral immune response 
against M2. Still, heterologous prime-boost schedules with 
M2 expressing plasmid DNA, followed by an adenoviral M2 
expression vector, can induce fairly strong anti-M2e antibody 
responses and protection that is in part mediated by T cells 
[25]. Heterologous prime boosts are more difficult to bring 
into practice than a single-shot or homologous booster vac-
cine regimen. However, the adult population seems to be 
already primed with M2, as evidenced by the presence of 
serum IgG that is reactive against M2 expressed by 293FT 
cells. Moreover, there is evidence that M2-specific antibod-
ies were boosted on infection with the H1N1 2009 pandemic 
virus [26]. Therefore, a single immunization with a vectored 
M2 expression vector or, preferentially, a recombinant M2e-
displaying VLP, may effectively boost the M2(e)-specific 
responses in adults, including elderly adults, but may not work 
as well in unprimed children.
M2E: A SIMPLE ANTIGEN THAT PROTECTS IN 
A COMPLEX WAY
Few influenza A viruses are susceptible to direct in vitro growth 
inhibition by M2e-specific IgG. Interestingly, the pandemic 
1957 H2N2, 1968 Hong Kong, and H1N1 USSR 1977 viruses 
belong to these exceptions and show a reduced plaque pheno-
type in the presence of 5 μg/mL of the M2e-specific monoclo-
nal antibody 14C2 [27]. On the other hand, M2e-immunized 
mice are protected against challenge with any influenza A virus 
that has been tested so far, as long as the severity of the chal-
lenge is relatively low (1–4 times the medial lethal dose). This 
discrepancy between the in vitro and in vivo antiviral effects 
of M2e-based vaccines is one reason why M2e is sometimes 
considered a “difficult target”: there is no easy way to set up an 
in vitro antiviral activity assay that recapitulates what probably 
happens in an M2e-immunized host. Such an assay is import-
ant because it could be standardized and used to predict the 
likelihood that the recipient of an M2e-based vaccine will be 
protected from disease, severe disease, or hospitalization due 
to influenza A.
Thanks to mouse genetics, antibody Fc engineering, 
and in vivo cell depletion studies, the mechanism of pro-
tection by M2e-specific IgG is now well established. The 
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consensus view is that IgG antibodies form immune com-
plexes on M2-expressing infected respiratory epithelial cells, 
which are recognized by activating Fcγ receptors expressed 
on alveolar macrophages (Figure 2) [28–30]. Interestingly, 
alveolar macrophages are also essential for the protection by 
broadly reactive HA-specific monoclonal antibodies, presum-
ably by performing antibody-dependent cellular phagocytosis 
of influenza virions and infected cells [31]. Given that there 
are very few M2 molecules present in influenza virions, it is 
likely that infected cells rather than virions are the target of 
antibody-dependent phagocytosis by alveolar macrophages. 
Elimination by alveolar macrophages of infected cells, and 
possibly of virions that are in the process of budding from the 
infected cells (macrophages prefer to engulf rigid particles 
[32]), would slow down the virus replication-induced disease 
process. 
Alveolar macrophages are also an important source of 
type I interferon (IFN) in response to respiratory viral infec-
tions [33, 34]. Type I IFN produced by alveolar macrophages 
can elicit a direct antiviral response in neighboring cells. In 
addition, type I  IFN induces expression of the chemokine 
CCL2, which recruits inflammatory monocytes that in turn 
can promote epithelial cell repair [35]. Interestingly, there is 
evidence that M2e-based immune protection may even stim-
ulate an adaptive immune response against other influenza 
proteins. First, nucleoprotein-specific CD8+ T-cell responses 
are comparable in saline- and M2e VLP–vaccinated mice 
after a sublethal influenza A virus challenge, even though the 
M2e-immune animals were very well protected, presenting 
with minimal loss of body weight [36, 37]. Possibly, anti–M2e 
IgG immune complexes are also recognized by dendritic cells, 
which thereby can take up, process, and present virus-con-
taining cell fractions to T cells in the draining lymph nodes. 
T-cell responses directed against the conserved internal influ-
enza gene products are important because they are associated 
with broad protection [38]. 
Second, M2e-specific CD4+ T cells can contribute to pro-
tection in their own right, but they also stimulate HA-specific 
antibodies on challenge virus infection [39]. So here is a vac-
cine candidate that is easy to produce, can provide very broad 
Matrix protein 2
Hemagglutinin
Neuraminidase
M2e-specific IgG
Activating FCγ receptor
Respiratory epithelial cell Respiratory epithelial cell Respiratory epithelial cell
Tissue repair
Dying epithelial cell
CCL2
Alveolar macrophage
Type I IFN
BM-derived
macrophage
Alveolar macrophage
Figure 2. Schematic representation of the likely mechanism of protection of matrix protein 2 (M2) ectodomain (M2e)–specific immunoglobulin (Ig) G. Airway epithelial 
cells infected with influenza A virus display hemagglutinin, neuraminidase, and M2 on their surface and bud off newly produced virions. M2 at the neck of the budding virion 
can be opsonized with anti–M2e IgG, which in turn is bound by activating Fcγ receptors on alveolar macrophages. This way, macrophages can take up budding virions and 
M2-containing membrane fractions from an infected respiratory epithelial cell. Infected cells that detach from neighboring cells can be opsonized by anti–M2e IgG and 
become phagocytosed by alveolar macrophages in an Fcγ receptor–dependent way. Activated macrophages can also produce type I  interferon (IFN), which has antiviral 
activity by inducing an antiviral state in the epithelial cells. In addition, type I IFN can up-regulate the chemokine CCL2, which attracts bone marrow–derived macrophages 
that promote tissue repair.
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protection against influenza A  virus challenge, and does not 
stop the host from mounting an immune response to other 
viral antigens on virus encounter. Why is this product not yet 
licensed? To answer that question, it is important to scrutinize 
M2e vaccination studies in hosts that are naturally susceptible 
to influenza and consider what has been learned from phase 
I clinical studies.
M2E-BASED VACCINES IN HUMANS
There is some evidence that an M2e-based vaccine approach 
can suppress influenza A  virus replication in ferrets. These 
carnivores are considered relevant for human influenza, given 
their susceptibility to human influenza virus isolates, the clin-
ical features they display on influenza virus infection, and the 
distribution of the virus receptors in their respiratory tract, 
which is similar to that in humans [40]. Ferrets that were immu-
nized with a vaccine comprising M2e linked to 2 different carri-
ers mounted robust M2e-specific serum IgG titers and showed 
reduced virus shedding in the lungs after challenge with PR8 
virus [41]. A 2017 study found that immunization of ferrets with 
bacteria-derived outer membrane vesicles displaying 4 tandem 
repeat copies of M2e reduced in lung virus titers more than a 
conventional influenza vaccine after challenge with H1N1 2009 
pandemic virus [42]. In pigs, modest protection against dis-
ease after aerosol challenge with a nebulized swine H1N1 virus 
(108 median tissue culture infective dose) was reported despite 
the mismatch of 6 amino acid residues between the vaccine 
(adjuvanted M2e VLPs) and challenge virus M2e [43]. Finally, 
M2e-based vaccines can partially protect chickens against 
experimental challenge with avian influenza viruses, including 
a highly pathogenic H5N1 strain [44, 45].
The scant data about the possible clinical benefit that anti-
M2e responses may provide look promising. First, preexisting 
humoral immunity to M2 (meaning reactivity of serum IgG 
with M2-expressing mammalian cells, thus primarily directed 
against M2e) showed a tendency toward an inverse correlation 
with the incidence of H1N1 2009 pandemic virus infection by 
age group in US residents [26]. Second, phase I clinical studies 
have shown that M2e-based vaccines are safe, although vol-
unteers who had received a low dose of a M2e-flagelin fusion 
protein, administered subcutaneously, presented with local 
and systemic adverse effects, most likely due to the Toll-like 
receptor 5–stimulating flagellin component (clinical trials 
NCT00819013, NCT00921973, NCT00921947, NCT00921206, 
NCT00603811, and NCT01184976). Finally, anti–M2e IgG can 
be protective in humans. This was shown in a placebo-con-
trolled, double-blind, controlled challenge study in humans 
with the recombinant human IgG1 monoclonal antibody 
TCN-032, which recognizes the highly conserved N-terminus 
of M2. Intravenous administration of TCN-032 at 40  mg/kg 
1 day after intranasal infection with a human H3N2 virus sig-
nificantly reduced the total daily symptoms compared with 
placebo treatment, by 35%, and resulted in 2-day-faster recov-
ery [46]. Importantly, the treatment was also safe.
FUTURE PERSPECTIVES FOR ANTI-M2E IMMUNE 
PROTECTION
The earliest patent applications on M2e-based vaccines are 
expired by now, but research and clinical development of these 
vaccines is still ongoing. The Research Institute of Influenza in St 
Petersburg (The Russian Federation) has started a phase I study to 
assess the safety and immunogenicity of a hepatitis B core–based 
particle carrying 4 copies of M2e inserted in the immunodomi-
nant loop of the hepatitis B core capsomer, and adjuvanted with 
Derinat (Liudmila Tsybalova, personal communication on May 22, 
2018, Technomedservia Pharmaceutical Company, Mironovskaya, 
Russia) [47]. The Theraclone treatment study showed that 500 µg/
mL of a monoclonal IgG1 antibody specific for M2e (assuming a 
total blood volume of 6 L in a normal healthy adult with an anti-
body dosing of 40 mg/kg) could bring clinical relief when adminis-
tered 1 day after experimental virus challenge [46]. 
It is highly unlikely that an active vaccination protocol could 
induce such a high peak, let  alone sustained, concentration 
of M2e-specific IgG in circulation. However, considering that 
only an estimated 0.2% of that monoclonal probably reached 
the lumen of the lungs, the estimated 10-µg/mL concentration 
of the TCN-032 antibody at the infection site may actually 
have done the therapeutic job [48]. Furthermore, prophylaxis 
is likely to require less antibody to suppress virus replication, 
perhaps 10-fold less, which would correspond to 1 µg/mL of 
antibody in the lung lumen. These are levels that may be attain-
able, at least in theory, with active mucosal immunization. To 
our knowledge  intranasal immunization studies in humans 
with M2e-based vaccine antigens have not been reported. In 
addition, an active vaccination strategy would induce a poly-
clonal immune response, which could have some advantages.
A universal influenza vaccine will very likely have a tremen-
dously beneficial economic and health impact when the next 
influenza pandemic strikes, provided that such a vaccine is 
stockpiled and can be distributed rapidly. Alternatively, such a 
vaccine could be implemented as part of childhood vaccination 
programs, which would require the induction of long-term 
immune protection. A disappointment in the phase I clinical 
study with M2e VLPs was the rapid decline in anti–M2e IgG 
titers over time, with end-point M2e IgG titers that were hardly 
above background levels 1  year after the first immunization. 
A  more sustainable immune response may be achieved with 
the right adjuvant, such as DepoVax (IMV Inc.) or AS01 (GSK) 
[49, 50]. Finally, for the M2e-based approaches, it is fair to state 
that broader protection comes with reduced potency, compared 
with conventional seasonal influenza vaccines. Therefore, an 
M2e vaccine will probably be developed further as one among 
multiple components of a broadly protective influenza vaccine. 
A possible scheme that can be envisioned is to combine M2e 
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with an HA stalk–based vaccine in a prime boost regimen 
within childhood vaccination programs. Such a combination 
vaccine could induce broadly reactive anti-influenza immunity 
and prevent severe disease in the very young.
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